BlackRock’s Regencell Bioscience RGC Stock Holding History

BlackRock’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$126K	Buy	4,957 +92	+2%	+$2.6K	﹤0.01%	4911
2025 Q4	$102K	Hold	4,865	–	–	﹤0.01%	4901
2025 Q3	$75.2K	Sell	4,865 -3,724	-43%	-$53.4K	﹤0.01%	4905
2025 Q2	$146K	Sell	8,589 -5,205	-38%	-$63.5K	﹤0.01%	4746
2025 Q1	$11.6K	Buy	13,794 +4,750	+53%	+$1.31K	﹤0.01%	5164
2024 Q4	$1.18K	Hold	9,044	–	–	﹤0.01%	5303
2024 Q3	$1.32K	Hold	9,044	–	–	﹤0.01%	5127
2024 Q2	$800	Hold	9,044	–	–	﹤0.01%	5211
2024 Q1	$1.07K	Hold	9,044	–	–	﹤0.01%	5201
2023 Q4	$2.5K	Hold	9,044	–	–	﹤0.01%	5232
2023 Q3	$3.33K	Hold	9,044	–	–	﹤0.01%	5271
2023 Q2	$5.17K	Hold	9,044	–	–	﹤0.01%	5310
2023 Q1	$6.16K	Hold	9,044	–	–	﹤0.01%	5361
2022 Q4	$6.47K	Hold	9,044	–	–	﹤0.01%	5501
2022 Q3	$8K	Hold	9,044	–	–	﹤0.01%	5603
2022 Q2	$8K	Buy	+9,044	New	+$6.82K	﹤0.01%	5646

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

BlackRock's RGC Position: Q1 2026 in Review

BlackRock increased its Regencell Bioscience (RGC) stake by 1.9% in Q1 2026, buying an estimated $2.6K and bringing the position to 4,957 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #4911.

BlackRock first reported a position in RGC in Q2 2022 and has held it in 16 quarters since. The position peaked at $146K in Q2 2025. 31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

BlackRock held 4,957 shares of Regencell Bioscience worth $126K as of Q1 2026.
BlackRock bought 92 Regencell Bioscience shares in Q1 2026, an estimated $2.6K.
Regencell Bioscience made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4911 holding.
BlackRock first reported a position in Regencell Bioscience in Q2 2022 and has held it in 16 quarters since.
BlackRock's Regencell Bioscience position peaked at $146K in Q2 2025.
31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.